Treatment of VCaP tumor–bearing mice with a single i.v. injection of 225Ac-KLK2 reduced tumor growth across multiple doses, with 110% TGI achieved at 500 nCi compared with control (Fig. 4B). Here, KLK2 is linked to neoplasm.